RxDoctor Payments Data

Cindy Silva, DO

Internal Medicine · Bethlehem, PANPI 1518121136

Payments from drug & device makers

$899in general payments, 2019–2025

Across 21 payments — averaging $42.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$532
  • Lilly USA, LLC$203
  • Exact Sciences$106
  • Pfizer$41
  • Boehringer Ingelheim$17

What the payments were for

  • Food & beverage$899100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen5$532
Lilly USA, LLC7$203
Exact Sciences6$106
Pfizer2$41
Boehringer Ingelheim1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$899 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$222,790
Medicare patients
435
Services billed
3,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$82,500
JardianceEmpagliflozin64$76,904
TradjentaLinagliptin17$21,077
JanuviaSitagliptin Phosphate13$19,633
FarxigaDapagliflozin Propanediol15$14,714
Breo ElliptaFluticasone/Vilanterol18$7,595
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate25$6,103
Rosuvastatin Calcium335$4,721
SynthroidLevothyroxine Sodium57$4,653
Atorvastatin Calcium399$4,564
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$4,314
Amlodipine Besylate423$3,323
Levothyroxine Sodium306$3,042
Omeprazole172$2,587
Metoprolol Succinate156$2,568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$17$97,98181 claims
PfizerEliquis$41$82,50082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →